Literature DB >> 12923172

Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine.

Daisuke Sugiyama1, Hiroyuki Kusuhara, Hirokazu Taniguchi, Shumpei Ishikawa, Yoshitane Nozaki, Hiroyuki Aburatani, Yuichi Sugiyama.   

Abstract

Oatp14/blood-brain barrier-specific anion transporter 1 (Slc21a14) is a novel member of the organic anion transporting polypeptide (Oatp/OATP) family. Northern blot analysis revealed predominant expression of Oatp14 in the brain, and Western blot analysis revealed its expression in the brain capillary and choroid plexus. Immunohistochemical staining indicated that Oatp14 is expressed in the border of the brain capillary endothelial cells. When expressed in human embryonic kidney 293 cells, Oatp14 transports thyroxine (T4; prothyroid hormone) (Km = 0.18 mum), as well as amphipathic organic anions such as 17beta estradiol-d-17beta-glucuronide (Km = 10 mum), cerivastatin (Km = 1.3 mum), and troglitazone sulfate (Km = 0.76 mum). The uptake of triiodothyronine (T3), an active form produced from T4, was significantly greater in Oatp14-expressed cells than in vector-transfected cells, but the transport activity for T3 was approximately 6-fold lower that for T4. The efflux of T4, preloaded into the cells, from Oatp14-expressed cells was more rapid than that from vector-transfected cells (0.032 versus 0.006 min-1). Therefore, Oatp14 can mediate a bidirectional transport of T4. Sulfobromophthalein, taurocholate, and estrone sulfate were potent inhibitors for Oatp14, whereas digoxin, p-aminohippurate, or leukotriene C4, or organic cations such as tetraetheylammonium or cimetidine had no effect. The expression levels of Oatp14 mRNA and protein were up- and down-regulated under hypo- and hyperthyroid conditions, respectively. Therefore, it may be speculated that Oatp14 plays a role in maintaining the concentration of T4 and, ultimately, T3 in the brain by transporting T4 from the circulating blood to the brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923172     DOI: 10.1074/jbc.M306933200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  79 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Blood-brain barrier genomics, proteomics, and new transporter discovery.

Authors:  Eric V Shusta
Journal:  NeuroRx       Date:  2005-01

Review 3.  Thyroid development and effect on the nervous system.

Authors:  Pilar Santisteban; Juan Bernal
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

Review 4.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 5.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Active efflux across the blood-brain barrier: role of the solute carrier family.

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  NeuroRx       Date:  2005-01

7.  Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.

Authors:  K Sakamoto; H Mikami; J Kimura
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

Review 8.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

9.  Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3'-triiodo-L-thyronine.

Authors:  Ainhoa Ceballos; Monica M Belinchon; Eduardo Sanchez-Mendoza; Carmen Grijota-Martinez; Alexandra M Dumitrescu; Samuel Refetoff; Beatriz Morte; Juan Bernal
Journal:  Endocrinology       Date:  2009-01-15       Impact factor: 4.736

10.  Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness.

Authors:  Liese Mebis; Yves Debaveye; Björn Ellger; Sarah Derde; Eric-Jan Ververs; Lies Langouche; Veerle M Darras; Eric Fliers; Theo J Visser; Greet Van den Berghe
Journal:  Crit Care       Date:  2009-09-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.